Allogeneic bone marrow transplantation for patients with thalassemia major

Allogeneic HSCT, so far the only curative treatment for TM, has evolved in the last 50 years. In 1981, the Seattle team successfully transplanted the first patient with TM. Since then, over 3000 patients have received HSCT throughout the world. The largest body of experience in this setting has been accrued in Pesaro, Italy. The use of HSCT has been continuously increasing in the last years and outcomes today have substantially improved compared with the past three decades. The current world-wide results indicate that 90% of patients survive HSCT while disease-free survival is around 80%. In this study, we report our experience in 132 patients affected by TM and treated with HSCT...